On Monday, Kymera Therapeutics hit an important performance benchmark, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 84, up from 79 the day before.
Hone Your Stock-Picking Skills By Focusing On These Factors
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains often have an RS Rating north of 80 as they launch their biggest runs.
Kymera Therapeutics is working on a consolidation with a 50.27 entry. See if the stock can clear the breakout price in volume at least 40% above average.
Kymera Therapeutics reported 0% EPS growth last quarter, while sales growth came in at -55%.
The company earns the No. 266 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
